Loading stock data…
Lifecore Biomedical (LFCR)
$4.31-0.09 (-2.05%)
Market ClosedLast close Sep 8
Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization that serves customers in the United States, Belgium, the Netherlands, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Lifecore Biomedical, Inc. in the Healthcare sector is trading at $4.31 with a market capitalization of $209M. Wall Street consensus targets $6.75 (3 analysts), implying a +56.6% move over the next 12 months. The stock is currently near its 52-week low of $3.63, remaining 27.2% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 45/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +56.6% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q2 2026 | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $34.17M↑ | $23.19M↓ | $31.11M↓ | $36.44M↑ | $35.15M |
| Gross Profit | $12.07M↑ | $4.46M↓ | $7.79M↓ | $13.98M↑ | $9.85M |
| Operating Income | $2.57M↑ | -$4.67M↓ | -$3.07M↓ | $2.90M↑ | -$2.18M |
| Net Income | -$6.16M↑ | -$14.98M↓ | -$9.99M↓ | -$1.15M↑ | -$14.77M |
Peer Comparison
JNJUNHPFE
Fundamentals
Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization that serves customers in the United States, Belgium, the Netherlands, and internationally. It provides services i...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$208.93M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
143.78%
Volume
Today's trading volume
185,383
Recent News
Core Thesis Behind Lifecore Biomedical (LFCR): Monetizing Excess Capacity
Greenhaven Road Capital, an investment management company, released its second-quarter 2026 investor letter. A copy of the letter can be downloaded here. The fund achieved an approximate 11% net return in the second quarter, indicating progress from the first quarter. Key changes to the portfolio will include lower concentration and increased investments with near-term catalysts, […]
Lifecore Biomedical (LFCR) Q2 2026 Earnings Call Transcript
Customer demand inflection expected in 2027 despite Q2 revenue decline.
Lifecore Biomedical, Inc. Q2 2026 Earnings Call Summary
Moby summary of Lifecore Biomedical, Inc.'s Q2 2026 earnings call
Lifecore Biomedical Inc (LFCR) (Q2 2026) Earnings Call Highlights: Strategic Wins and Capacity ...
Despite a 6.2% revenue dip, Lifecore secures nine new programs and reaffirms 2026 guidance, positioning for a 200% demand surge from its largest customer by 2028.
Lifecore Biomedical Q2 Earnings Call Highlights
Lifecore Biomedical (NASDAQ:LFCR) reaffirmed its 2026 revenue and adjusted EBITDA guidance while outlining plans to support sharply higher fill-finish demand from its largest customer beginning in 2027. For the second quarter ended June 30, 2026, the contract development and manufacturing organizat